Company Description
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in the United States, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally.
The company operates through three reportable segments: Sample Management Solutions, Multiomics, and B Medical Systems.
The Sample Management Solutions segment provides sample management products and solutions, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services.
This segment also offers consultation services to clients throughout their experimental design and implementation processes.
The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, synthesis editing, and related services.
The B Medical Systems segment manufactures and distributes temperature-controlled storage and transportation solutions to governments, health institutions, and non-government organizations.
The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021.
Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.
| Country | United States |
| Founded | 1978 |
| IPO Date | Feb 1, 1995 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 3,300 |
| CEO | John P. Marotta |
Contact Details
Address: 200 Summit Drive, 6th Floor Burlington, Massachusetts 01803 United States | |
| Phone | 888 229 3682 |
| Website | azenta.com |
Stock Details
| Ticker Symbol | AZTA |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0000933974 |
| CUSIP Number | 114340102 |
| ISIN Number | US1143401024 |
| Employer ID | 04-3040660 |
| SIC Code | 3559 |
Key Executives
| Name | Position |
|---|---|
| John P. Marotta | President, Chief Executive Officer and Director |
| Jason W. Joseph J.D. | Senior Vice President, General Counsel and Corporate Secretary |
| Lawrence Y. Lin | Executive Vice President and Chief Financial Officer |
| Violetta Hughes | Vice President and Chief Accounting Officer |
| Michael Paulo | Vice President and Chief Information and Digital Officer |
| Yvonne Perron | Vice President of Financial Planning and Analysis and Investor Relations |
| John E. O'Brien | Senior Vice President of Corporate Development |
| Olga Pirogova | Senior Vice President and Chief Human Resources Officer |
| J. Robert Woodward | Senior Vice President of Global Quality and Regulatory |
| Dr. Ginger Zhou Ph.D. | Senior Vice President and GM of the Genewiz Multiomics and Synthesis Solutions |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 17, 2024 | ARS | Filing |
| Dec 17, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Dec 17, 2024 | DEF 14A | Other definitive proxy statements |
| Dec 6, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 27, 2024 | 10-K | Annual Report |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 4, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 4, 2024 | 8-K | Current Report |
| Oct 31, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |